Piper Sandler Maintains Overweight on AtriCure, Raises Price Target to $60
Piper Sandler analyst Matt O'Brien maintains AtriCure (NASDAQ:ATRC) with a Overweight and raises the price target from $50 to $60.
Read original at benzingaStocks · News reference
Top 3 Health Care Stocks That May Implode This Month
RSI warning: 3 overbought health care stocks could be flashing a real warning to investors with high momentum trading preferences
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 29, 2026, 12:45 PM
- Checked
- Jul 29, 2026, 12:44 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Atrial Fibrillation Treatment Devices Market Trends and Forecast, 2035 | Includes Profiles of Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic
The global atrial fibrillation treatment devices market is expected to grow at a 13.1% CAGR from $9.6 billion in 2026 to $29 billion by 2035, driven by aging populations, rising AF prevalence affecting 50-60 million people worldwide, and increasing adoption of advanced ablation and left atrial appendage closure technologies. Pulsed field ablation is forecast to generate over 60% of market revenue by 2035, while North America will retain approximately 50% of global market share. Asia-Pacific is expected to register the fastest regional growth.
Read original at globenewswire-incAnalog Devices To Rally Around 81%? Here Are 10 Top Analyst Forecasts For Monday
Top analysts change outlook on top names. See all rating changes, including upgrades/downgrades, on analyst ratings page. Follow other analysts.
Read original at benzingaBTIG Maintains Buy on AtriCure, Raises Price Target to $55
Read original at benzingaCanaccord Genuity Initiates Coverage On Incyte with Buy Rating, Announces Price Target of $152
Canaccord Genuity analyst John Newman initiates coverage on Incyte (NASDAQ:INCY) with a Buy rating and announces Price Target of $152.
Read original at benzingaHC Wainwright & Co. Reiterates Buy on Incyte, Maintains $150 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $150 price target.
Read original at benzinga